Screener
Mineralys Therapeutics, Inc. MLYS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Accrued interest receivable | 289 | 52 |
| Prepaid, other current assets, and other assets | (1,948) | (4,396) |
| Accounts payable and accrued liabilities | (402) | (1,546) |
| Net cash used in operating activities | (39,471) | (45,487) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of marketable securities | (347,443) | (127,876) |
| Maturities of marketable securities | 302,500 | 35,000 |
| Net cash used in investing activities | (44,943) | (92,876) |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s operating cash flow?
- Mineralys Therapeutics, Inc. (MLYS) reported operating cash flow of -$39.47M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Mineralys Therapeutics, Inc.'s operating cash flow increased by 13.2% year-over-year, from -$45.49M to -$39.47M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s operating cash flow?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s operating cash flow has grown at a 69.5% compound annual growth rate (CAGR), from -$29.22M to -$142.42M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Mineralys Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude